Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumors antigen peptide variants: Crucial role of interaction kinetics on functional outcomes

European Journal of Immunology

Volumn 32, Issue 11, 2002, Pages 3285-3293

  Dutoit, Valérie ^a   Guillaume, Philippe ^b   Cerottini, Jean Charles ^b   Romero, Pedro ^a   Valmori, Danila ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

CTL; Human; MHC; T cell receptor; Tumor immunity

Indexed keywords

ALANINE; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

AMINO ACID SUBSTITUTION; BINDING AFFINITY; BINDING KINETICS; CELL ASSAY; CELL CLONE; CHEMICAL REACTION KINETICS; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN VARIANT; REVIEW;

ANTIGENS, NEOPLASM; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KINETICS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036858973     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200211)32:11<3285::AID-IMMU3285>3.0.CO;2-9     Document Type: Review

References (24)

1. Kersh, G. J. and Allen, P. M., Essential flexibility in the T-cell recognition of antigen. Nature 1996. 380: 495-498.
2. McKeithan, T. W., Kinetic proofreading in T-cell receptor signal transduction. Proc. Natl. Acad. Sci. USA 1995. 92: 5042-5046.
3. Rabinowitz, J. D., Beeson, C., Lyons, D. S., Davis, M. M. and McConnell, H. M., Kinetic discrimination in T-cell activation. Proc. Natl. Acad. Sci. USA 1996. 93: 1401-1405.
4. Altman, J. D., Moss, P. A., Goulder, P. J., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J. and Davis, M. M., Phenotypic analysis of antigen-specific T lymphocytes. Science 1996. 274: 94-96.
5. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 1998. 187: 1395-1402.
6. Gallimore, A., Glithero, A., Godkin, A., Tissot, A. C., Pluckthun, A., Elliott, T., Hengartner, H. and Zinkernagel, R., Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 1998. 187: 1383-1393.
7. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J. L., Lienard, D., Cerottini, J. C. and Cerundolo, V., Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 1998. 188: 1641-1650.
8. Burrows, S. R., Kienzle, N., Winterhalter, A., Bharadwaj, M., Altman, J. D. and Brooks, A., Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J. Immunol. 2000. 165: 6229-6234.
9. Whelan, J. A., Dunbar, P. R., Price, D. A., Purbhoo, M. A., Lechner, F, Ogg, G. S., Griffiths, G., Phillips, R. E., Cerundolo, V. and Sewell, A. K., Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J. Immunol. 1999. 163: 4342-4348.
10. Yee, C., Savage, P. A., Lee, P. P., Davis, M. M. and Greenberg, P. D., Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 1999. 162: 2227-2234.
11. Derby, M. A., Wang, J., Margulies, D. H. and Berzofsky, J. A., Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Int. Immunol. 2001. 13: 817-824.
12. Dutoit, V., Rubio-Godoy, V., Dietrich, P. Y., Quiqueres, A. L., Schnuriger, V., Rimoldi, D., Lienard, D., Speiser, D., Guillaume, P., Batard, P., Cerottini, J. C., Romero, P. and Valmori, D., Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 2001. 61: 5850-5856.
13. Dutoit, V., Rubio-Godoy, V., Doucey, M. A., Batard, P., Lienard, D., Rimoldi, D., Speiser, D., Guillaume, P., Cerottini, J. C., Romero, P. and Valmori, D., Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J. Immunol. 2002. 168: 1167-1171.
14. Kalergis, A. M., Boucheron, N., Doucey, M. A., Palmieri, E., Goyarts, E. C., Vegh, Z., Luescher, I. F. and Nathanson, S. G., Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2001. 2: 229-234.
15. Rubio-Godoy, V., Dutoit, V., Rimoldi, D., Lienard, D., Lejeune, F., Speiser, D., Guillaume, P., Cerottini, J. C., Romero, P. and Valmori, D., Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc. Natl. Acad. Sci. USA 2001. 98: 10302-10307.
16. Lyons, D. S., Lieberman, S. A., Hampl, J., Boniface, J. J., Chien, Y., Berg, L. J. and Davis, M. M., A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996. 5: 53-61.
17. Sloan-Lancaster, J. and Allen, P. M., Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 1996. 14: 1-27.
18. Germain, R. N. and Margulies, D. H., The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 1993. 11: 403-450.
19. Sykulev, Y., Vugmeyster, Y., Brunmark, A., Ploegh, H. L. and Eisen, H. N., Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. Immunity 1998. 9: 475-483.
20. Kessler, B. M., Bassanini, P., Cerottini, J. C. and Luescher, I. F., Effects of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. J. Exp. Med. 1997. 185: 629-640.
21. Daniels, M. A. and Jameson, S. C., Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J. Exp. Med. 2000. 191: 335-346.
22. + T cells. J. Immunol. 2001. 166: 7009-7013.
23. + T cell response to the cancer testis antigen NYESO-1 in melanoma patients. Cancer Res. 2000. 60: 4499-4506.
24. Huang, L. Q., Brasseur, F, Serrano, A., De Plaen, E., van der Bruggen, P., Boon, T. and Van Pel, A., Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J. Immunol. 1999. 162: 6849-6854.